Interim Analysis of Immunogenicity to the Vector Capsid and Transgene-Expressed Human FVIII in a Phase-1/2 Clinical Study of Bmn 270, an AAV5-Mediated Gene Therapy for Hemophilia a
Brian Long(BioMarin (United States)), Becky Schweighardt(BioMarin (United States)), Nancy Pryer(Novartis (United States)), Klaudia Kuranda(Spark Therapeutics (United States)), Benjamin Kim(Stanford University), Glenn F. Pierce(Hemophilia Federation of America), Kehu Yang(Nanjing Medical University), P. Véron(Genethon (France)), Christian Vettermann(Eureka Therapeutics (United States)), Federico Mingozzi(Spark Therapeutics (United States)), Wing Yen Wong(BioMarin (United States)), Romain Hardet(Inserm)
Cited by 1
Related Papers
Proteomic Analysis of Dendritic Cell-Derived Exosomes: A Secreted Subcellular Compartment Distinct from Apoptotic Vesicles
|The Journal of Immunology|2001|1.5k
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
|Nature|2013|735
Overcoming Preexisting Humoral Immunity to AAV Using Capsid Decoys
|Science Translational Medicine|2013|346